The formulation of Halofantrine as either non-solubilising PEG 6000 or solubilising lipid based solid dispersions: Physical stability and absolute bioavailability assessment
- 1 September 2000
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 205 (1-2) , 65-78
- https://doi.org/10.1016/s0378-5173(00)00485-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Characteristics and Significance of the Amorphous State in Pharmaceutical SystemsJournal of Pharmaceutical Sciences, 1997
- A physicochemical Basis for the Effect of Food on the Absolute Oral Bioavailability of HalofantrineJournal of Pharmaceutical Sciences, 1996
- A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditionsJournal of Pharmaceutical and Biomedical Analysis, 1995
- Molecular Mobility of Amorphous Pharmaceutical Solids Below Their Glass Transition TemperaturesPharmaceutical Research, 1995
- Clinical Pharmacokinetics of HalofantrineClinical Pharmacokinetics, 1994
- Solid dispersions of oxazepamInternational Journal of Pharmaceutics, 1993
- HalofantrineDrugs, 1992
- The effect of incorporation of indomethacin with polyethylene glycol 6000 in a solid dispersion on itsin vivo properties in the ratInflammation Research, 1984
- Pharmaceutical Applications of Solid Dispersion SystemsJournal of Pharmaceutical Sciences, 1971
- Oral Absorption of Griseofulvin in Dogs: Increased Absorption via Solid Dispersion - in Polyethylene Glycol 6000Journal of Pharmaceutical Sciences, 1970